Neurodegenerative Disease Market Synopsis:
Neurodegenerative Disease Market Size Was Valued at USD 14.72 Billion in 2023, and is Projected to Reach USD 24.22 Billion by 2032, Growing at a CAGR of 5.69 % From 2024-2032.
The Neurodegenerative Disease Market refers to the market for products associated with the prevention, treatment, and control of chronic and progressive diseases of the nervous system. These diseases include Alzheimer’s, Parkinson’s, Huntington’s and Amyotrophic Lateral Sclerosis (ALS), all of which result from the closing down of neurons hence are life-altering diseases.
Market segment has been steadily growing over the recent past due to the rising number of neurodegenerative diseases worldwide, and among the elderly people. With global population aging, diseases like Alzheimer’s and Parkinson’s will become more widespread, increasing public’s need for new therapies. Novelty in terms of disease-modifying drugs, symptomatic treatment, diagnostics, and determination of efficacy has soared high and largely played an important role in the progress route for this market. Secondly, the incorporation of artificial intelligence in tests has led to increased early diagnosis besides extending the chances of intervention.
Autonomous communities are rising their rates of expenditure on research and development; centred on the aetiology of neurodegenerative diseases. Extension of new therapies has also been promoted through partnerships and collaborations between private organizations and public entities especially the pharmaceutical firms. However, there has been issues in the market which include high costs of drug development, fewer treatment options for diseases, legal requirements and compliance.
Neurodegenerative Disease Market Trend Analysis:
Personalized Medicine and Biomarker Advancements
- Targeted therapy and biomarkers have emerged as pivotal trends in the evolving neurodegenerative disease market. The identification of protein biomarkers, such as beta-amyloid and tau in Alzheimer’s disease, has significantly enhanced early diagnosis, enabling clinicians to initiate treatment during the initial stages of disease progression. This advancement has improved patient outcomes & has also facilitated the development of more personalized therapeutic strategies. Ongoing genetic research has uncovered various susceptibility genes and molecular pathways that serve as promising targets for precision medicine.
- By tailoring treatments to an individual’s genetic and biochemical profile, these innovations are expected to transform standard care protocols. As a result, patients may experience extended lifespans and improved quality of life. Such targeted approaches are anticipated to enhance clinical trial efficacy by reducing heterogeneity in study populations and improving response rates.
Expanding Pipeline of Disease-Modifying Therapies
- The increasing focus on disease-modifying therapies (DMTs) is a key driver of growth in the neurodegenerative diseases market. Unlike traditional treatments that mainly address symptoms, DMTs aim to alter the underlying progression of these disorders, potentially offering long-term benefits to patients. This paradigm shift is fueling significant investment from leading biopharmaceutical companies. These firms are channeling resources into developing innovative approaches such as monoclonal antibodies, gene therapies, and small-molecule drugs that target disease mechanisms at the molecular level.
- By addressing unmet clinical needs and potentially slowing or halting disease progression, these therapies not only promise improved patient outcomes but also present a substantial commercial opportunity. If successfully developed and approved, such therapies could redefine standards of care while generating lucrative revenue streams for pharmaceutical developers over the coming years.
Neurodegenerative Disease Market Segment Analysis:
Neurodegenerative Disease Market is Segmented on the basis of Indication Type, Drug Type, Route of Administration, and Region.
By Indication Type, Parkinson's Disease segment is expected to dominate the market during the forecast period
- The Parkinson’s Disease segment is projected to dominate the global market for space and technology-assisted therapeutic interventions due to its high prevalence and the increasing demand for advanced treatment solutions. Parkinson’s disease affects millions of individuals worldwide and is characterized by both motor symptoms such as tremors, muscle rigidity, and bradykinesia and non-motor symptoms like depression, sleep disturbances, and dementia.
- Technological advances, particularly in therapies like deep brain stimulation (DBS), wearable symptom monitoring, and drug delivery enhancements that amplify the effect of levodopa, are significantly fueling market growth. Rising awareness among healthcare professionals and patients, along with improvements in early diagnostic techniques, are facilitating earlier and more accurate detection of the disease. These combined factors are contributing to the rapid expansion of this segment, positioning it for sustained growth in the near future.
By Drug Type, the N-methyl-D-aspartate Receptor antagonists segment expected to hold the largest share
- The N-methyl-D-aspartate (NMDA) Receptor Antagonists segment is projected to dominate the Alzheimer's treatment market due to its critical therapeutic role in managing symptoms associated with Alzheimer's disease and other neurodegenerative disorders. NMDA receptor antagonists, such as memantine, function by modulating glutamate activity a neurotransmitter involved in learning and memory that, when dysregulated, contributes to neuronal damage and cognitive decline.
- Memantine’s effectiveness in slowing disease progression and improving cognitive performance has solidified its clinical importance. Increasing prevalence of Alzheimer’s disease worldwide has driven demand for this class of drugs. Ongoing research and clinical trials aimed at enhancing the efficacy, bioavailability, and safety profile of NMDA receptor antagonists further reinforce their market strength. As newer formulations and combination therapies emerge, the segment is expected to maintain a leading market share in the foreseeable future.
Neurodegenerative Disease Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America will continue to lead the growth of the overall neurodegenerative disease market across the forecast period due to higher revenues from well-developed healthcare facilities and a substantial focus on R&D along with the rising incidence of neurological disorders in this region. Currently, the United States constitutes the leading nation for R&D investment in Central & Eastern Europe, backed by umbrella organization pharmaceuutical company firms, lifted public awareness, and government encouraging policies aimed at enhancing neurological ailments cure.
- The latter also take advantage of early diagnostic methods and increasing use of precision medicine so important in treatment of complex neurodegenerative diseases. They pointed out that Canada also plays a role in the regional market because there are more investment and more efforts to improve the therapeutics for neurodegenerative diseases. In combination, they guarantee North America’s position on this rather new and quickly developing market.
Active Key Players in the Neurodegenerative Disease Market:
- AbbVie Inc. (USA)
- Acorda Therapeutics, Inc. (USA)
- Biogen Inc. (USA)
- Eisai Co., Ltd. (Japan)
- Eli Lilly and Company (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- GlaxoSmithKline plc (UK)
- Johnson & Johnson Services, Inc. (USA)
- Lundbeck A/S (Denmark)
- Merck & Co., Inc. (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Sanofi S.A. (France)
- Takeda Pharmaceutical Company Limited (Japan)
- UCB S.A. (Belgium), and Other Active Players
|
Global Neurodegenerative Disease Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 14.72 Billion |
|
Forecast Period 2024-32 CAGR: |
5.69 % |
Market Size in 2032: |
USD 24.22 Billion |
|
Segments Covered: |
By Indication Type |
|
|
|
By Drug Type |
|
||
|
By Route of Administration |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Neurodegenerative Disease Market by Vehicle Type
4.1 Neurodegenerative Disease Market Snapshot and Growth Engine
4.2 Neurodegenerative Disease Market Overview
4.3 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs): Geographic Segmentation Analysis
Chapter 5: Neurodegenerative Disease Market by Battery Type
5.1 Neurodegenerative Disease Market Snapshot and Growth Engine
5.2 Neurodegenerative Disease Market Overview
5.3 Lithium-Ion Solid-State Nickel-Metal Hydride
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Lithium-Ion Solid-State Nickel-Metal Hydride: Geographic Segmentation Analysis
Chapter 6: Neurodegenerative Disease Market by Range
6.1 Neurodegenerative Disease Market Snapshot and Growth Engine
6.2 Neurodegenerative Disease Market Overview
6.3 150-300 miles Below 150 miles Above 300 miles
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 150-300 miles Below 150 miles Above 300 miles: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Neurodegenerative Disease Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBVIE INC. (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ACORDA THERAPEUTICS INC. (USA)
7.4 BIOGEN INC. (USA)
7.5 EISAI CO. LTD. (JAPAN)
7.6 ELI LILLY AND COMPANY (USA)
7.7 F. HOFFMANN-LA ROCHE AG (SWITZERLAND)
7.8 GLAXOSMITHKLINE PLC (UK)
7.9 JOHNSON & JOHNSON SERVICES INC. (USA)
7.10 LUNDBECK A/S (DENMARK)
7.11 MERCK & CO. INC. (USA)
7.12 NOVARTIS AG (SWITZERLAND)
7.13 PFIZER INC. (USA)
7.14 SANOFI S.A. (FRANCE)
7.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN)
7.16 UCB S.A. (BELGIUM)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Neurodegenerative Disease Market By Region
8.1 Overview
8.2. North America Neurodegenerative Disease Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Vehicle Type
8.2.4.1 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
8.2.5 Historic and Forecasted Market Size By Battery Type
8.2.5.1 Lithium-Ion Solid-State Nickel-Metal Hydride
8.2.6 Historic and Forecasted Market Size By Range
8.2.6.1 150-300 miles Below 150 miles Above 300 miles
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Neurodegenerative Disease Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Vehicle Type
8.3.4.1 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
8.3.5 Historic and Forecasted Market Size By Battery Type
8.3.5.1 Lithium-Ion Solid-State Nickel-Metal Hydride
8.3.6 Historic and Forecasted Market Size By Range
8.3.6.1 150-300 miles Below 150 miles Above 300 miles
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Neurodegenerative Disease Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Vehicle Type
8.4.4.1 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
8.4.5 Historic and Forecasted Market Size By Battery Type
8.4.5.1 Lithium-Ion Solid-State Nickel-Metal Hydride
8.4.6 Historic and Forecasted Market Size By Range
8.4.6.1 150-300 miles Below 150 miles Above 300 miles
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Neurodegenerative Disease Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Vehicle Type
8.5.4.1 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
8.5.5 Historic and Forecasted Market Size By Battery Type
8.5.5.1 Lithium-Ion Solid-State Nickel-Metal Hydride
8.5.6 Historic and Forecasted Market Size By Range
8.5.6.1 150-300 miles Below 150 miles Above 300 miles
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Neurodegenerative Disease Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Vehicle Type
8.6.4.1 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
8.6.5 Historic and Forecasted Market Size By Battery Type
8.6.5.1 Lithium-Ion Solid-State Nickel-Metal Hydride
8.6.6 Historic and Forecasted Market Size By Range
8.6.6.1 150-300 miles Below 150 miles Above 300 miles
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Neurodegenerative Disease Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Vehicle Type
8.7.4.1 Battery Electric Vehicles (BEVs) Plug-in Hybrid Electric Vehicles (PHEVs) Hybrid Electric Vehicles (HEVs)
8.7.5 Historic and Forecasted Market Size By Battery Type
8.7.5.1 Lithium-Ion Solid-State Nickel-Metal Hydride
8.7.6 Historic and Forecasted Market Size By Range
8.7.6.1 150-300 miles Below 150 miles Above 300 miles
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Neurodegenerative Disease Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 14.72 Billion |
|
Forecast Period 2024-32 CAGR: |
5.69 % |
Market Size in 2032: |
USD 24.22 Billion |
|
Segments Covered: |
By Indication Type |
|
|
|
By Drug Type |
|
||
|
By Route of Administration |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
